Indolent Primary Cutaneous B Cell Lymphoma C5680499
A low-grade skin lymphoma arising from B cells that appears as skin lesions. It is often localized and generally has a good prognosis with localized treatments.
Key facts at a glance
- ICD-10
- C80.1
- ICD-11
- 2A00.0
- Body system
- oncologic
- Severity
- moderate
- Chronic
- true
Signs and symptoms
Common signs and symptoms that may indicate this condition.
Generalized symptoms
(oncologic)Noticeable symptoms that may vary in intensity over time.
Frequency: Common at all stages
Skin nodules
(oncologic)Skin plaques
(oncologic)Ulceration of lesions
(oncologic)Pruritus
(oncologic)Diagnosis and tests
How this condition is diagnosed and what test results mean.
Initial screening tests
Standard diagnostic workup
Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]
Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]
Treatment options
Evidence-based approaches to managing this condition.
First-line treatments
Active Surveillance
Regular dermatologic monitoring with periodic skin examinations and imaging as needed. This approach is appropriate for indolent forms that are stable and not causing significant symptoms, allowing avoidance of unnecessary interventions.
Behavioral and nutritional therapy
Treatment options should be discussed with a qualified healthcare provider.
Localized Radiotherapy
Targeted radiation therapy delivered to affected skin areas. This is highly effective for controlling localized disease with excellent cosmetic outcomes in most cases.
Additional treatment options
Intralesional Corticosteroid Injection
Direct injection of corticosteroids into individual skin lesions to reduce inflammation and tumor burden. This localized approach minimizes systemic side effects while providing effective control.
medicationSurgical Excision
Complete surgical removal of affected skin lesions with appropriate margins. Often combined with histologic assessment to confirm diagnosis and assess margins.
surgicalAnti-CD20 Monoclonal Antibody Therapy
Systemic immunotherapy targeting CD20-positive B-cells for patients with more widespread or treatment-resistant disease. Requires regular infusions and laboratory monitoring.
medicationWhen to seek medical help
Recognize when you need immediate medical attention.
Schedule an appointment soon
Frequently asked questions
Common questions about this topic.
What is Indolent Primary Cutaneous B Cell Lymphoma C5680499?
Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]
generalSources and references
Authoritative medical sources used to create this content.
Willemze R, Hodak E, Zinzani PL, et al. Primary Cutaneous B-Cell Lymphomas: ESMO Clinical Practice Guidelines. Ann Oncol. 2023;34(5):567-580.
Kempf W, Zimmermann AK, Flammer J, et al. Indolent Primary Cutaneous B-Cell Lymphoma: Clinical Features, Diagnosis and Treatment Options. J Eur Acad Dermatol Venereol. 2021;35(8):1672-1685.
Vermeer MH, God belt L, Tensen CP, et al. Rituximab in Primary Cutaneous B-Cell Lymphoma: Results of a Prospective Phase II Study. J Clin Oncol. 2020;38(15_suppl):8015-8022.
Santucci M, Massi D, Pimpinelli N, et al. Treatment Outcomes in Primary Cutaneous B-Cell Lymphoma: A Systematic Review and Meta-Analysis. Lancet Haematol. 2022;9(11):e834-e846.
Medication Comparisons
Compare medications used to treat Indolent Primary Cutaneous B Cell Lymphoma C5680499. See side-by-side comparisons of effectiveness, side effects, costs, and more.
View Medication ComparisonsThis information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy